Clinical Trials Logo

Gastric Antral Vascular Ectasia clinical trials

View clinical trials related to Gastric Antral Vascular Ectasia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04388150 Completed - Clinical trials for Gastric Antral Vascular Ectasia

Efficacy of Narrow Band Spectrum Endoscopy for the Diagnosis of Gastric Antral Vascular Ectasia in Patients With Liver Cirrhosis

Start date: November 11, 2019
Phase:
Study type: Observational

the study aims to evaluate the role of similar technology of Narrow Band Imaging VIST video intelligent staining technology in the diagnosis of Gastric Antral Vascular ectasia in cirrhotic patients

NCT ID: NCT01601639 Completed - Clinical trials for Gastric Antral Vascular Ectasia

Endoscopic Band Ligation Versus Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial

Start date: September 2012
Phase: Phase 3
Study type: Interventional

The investigators goal is to compare the standard argon plasma coagulation (APC) treatment with endoscopic band ligation (EBL) in patients with Gastric Antral Vascular Ectasia.

NCT ID: NCT00964496 Completed - Clinical trials for Obscure Gastrointestinal Bleeding

Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation

Start date: November 2004
Phase: Phase 2
Study type: Interventional

Background: Repeated episodes of bleeding from gastrointestinal vascular malformations refractory to endoscopic or surgical therapy often pose a major therapeutic challenge. Methods: The investigators performed a randomized, parallel controlled study of thalidomide as a therapy for recurrent gastrointestinal bleeding due to vascular malformation. Patients with at least six episodes of bleeding in the prior year due to vascular malformation were randomly grouped, prescribed a four-month regimen of either 25 mg of thalidomide or 100 mg of iron orally four times daily, and monitored for at least one year. The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months and the cessation of bleeding. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. Secondary outcomes included the participants dependent on blood transfusions and changes from baseline in transfused packed red cell units, bleeding episodes, bleeding durations, and hemoglobin levels at 12 months. Statistical significance was defined at P < 0.05.

NCT ID: NCT00587405 Completed - Watermelon Stomach Clinical Trials

Cyrotherapy vs. APC in GAVE

Start date: December 2007
Phase: Phase 2/Phase 3
Study type: Interventional

To see if either method of treatment for Watermelon Stomach shows better results